Evaluation of Hereditary Cancer Educational Videos

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

43 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-04-05

Study Completion Date

2027-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To learn if educational videos can help participants be more informed about hereditary cancers (ones that run in the family).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Web-Based Family Outreach Program for Cancer Prevention in High-Risk Families

NCT02337452

Malignant Neoplasm

ACTIVE_NOT_RECRUITING

Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)

NCT00829959

Breast Cancer Ovarian Cancer

COMPLETED

Genetic Counseling for Breast Cancer Survivors (GC for BC)

NCT02451735

Breast Cancer

COMPLETED NA

Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention

NCT07010315

Liver Cancer

RECRUITING

Melanoma Risk-Reduction Among Patients and Family Members

NCT00510302

Melanoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Objective

Determine the impact of educational videos on:

* Participant's hereditary cancer knowledge.
* Participant's confidence to share hereditary cancer information with family members.

Secondary Objective

* Determine impact of educational videos on participant's confidence to undergo hereditary cancer screening.
* Identify opportunities to tailor and improve the educational video's content, style, and understandability per participant preferences and feedback.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hereditary Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Interview Study

In the interview study, participants will watch the video, then complete an interview. This will take about 50 minutes.

Interview Study

Intervention Type BEHAVIORAL

All study participants will have the following demographic information collected from their medical records:

* Sex (Male/Female/Other)
* Date of birth
* Preferred language (English/Spanish)
* Health insurance status (for example: private insurance, HCHD "gold card")
* Cancer diagnosis (if yes: cancer type/organ, date of pathology diagnosis)
* Genetic testing result (gene with pathogenic/likely pathogenic variant)
* Date of genetic testing result
* Date of documented result disclosure.

Survey Study

In the survey study, participants will complete a survey about your education and complete a quick test about your knowledge of hereditary cancer. Participants will then watch the video. complete another survey similar to the one before the video. This should take about 30 minutes.

Survey Study

Intervention Type BEHAVIORAL

All study participants will have the following demographic information collected from their medical records:

* Sex (Male/Female/Other)
* Date of birth
* Preferred language (English/Spanish)
* Health insurance status (for example: private insurance, HCHD "gold card")
* Cancer diagnosis (if yes: cancer type/organ, date of pathology diagnosis)
* Genetic testing result (gene with pathogenic/likely pathogenic variant)
* Date of genetic testing result
* Date of documented result disclosure.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Interview Study

All study participants will have the following demographic information collected from their medical records:

* Sex (Male/Female/Other)
* Date of birth
* Preferred language (English/Spanish)
* Health insurance status (for example: private insurance, HCHD "gold card")
* Cancer diagnosis (if yes: cancer type/organ, date of pathology diagnosis)
* Genetic testing result (gene with pathogenic/likely pathogenic variant)
* Date of genetic testing result
* Date of documented result disclosure.

Intervention Type BEHAVIORAL

Survey Study

All study participants will have the following demographic information collected from their medical records:

* Sex (Male/Female/Other)
* Date of birth
* Preferred language (English/Spanish)
* Health insurance status (for example: private insurance, HCHD "gold card")
* Cancer diagnosis (if yes: cancer type/organ, date of pathology diagnosis)
* Genetic testing result (gene with pathogenic/likely pathogenic variant)
* Date of genetic testing result
* Date of documented result disclosure.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants of The Harris Health System Lyndon B. Johnson (LBJ) Hospital outpatient oncology clinics (i.e., Gynecologic Oncology, Medical Oncology).
2. 18 years of age or older.
3. Speaks and/or reads English or Spanish.
4. Has a pathogenic or likely pathogenic variant (mutation) in BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, and/or EPCAM on germline genetic testing.
5. Has a documented genetic testing results disclosure encounter (i.e. telephone call, follow-up appointment).

Exclusion Criteria

1. No longer receives outpatient care at LBJ Hospital at time of recruitment.
2. Has only a variant of uncertain significance in BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, and/or EPCAM.
3. Has only a pathogenic or likely pathogenic variant in gene other than BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, or EPCAM.
4. Is unwilling, unable, or requires a legally authorized representative to provide informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No